Abstract: The presence of analytes can be detected in the bodily fluid using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (ECS) in devices, such as handheld point-of-care devices. The devices, as well as systems and methods, utilize using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (EIS) in combination with an antibody or other target-capturing molecule on a working electrode. Imaginary impedance or phase shift, as well as background subtraction, also may be utilized.

Abstract: The presence of analytes can be detected in the bodily fluid using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (ECS) in devices, such as handheld point-of-care devices. The devices, as well as systems and methods, utilize using Electrochemical Impedance Spectroscopy (EIS) or Electrochemical Capacitance Spectroscopy (EIS) in combination with an antibody or other target-capturing molecule on a working electrode. Imaginary impedance or phase shift, as well as background subtraction, also may be utilized.

Abstract: Some systems include a memory, and a processor coupled to the memory, wherein the processor is configured to: identify one or more spatial markers in a medical data-based image of a patient, identify one or more spatial markers in a real-time perceived image of the patient, wherein the one or more spatial markers in the medical data-based image correspond to an anatomical feature of the patient and the one or more spatial markers in the real-time perceived image correspond to the anatomical feature of the patient, superimpose the medical data-based image of the patient with the real-time perceived image of the patient, and align the one or more spatial markers in the medical data-based image with the respective one or more spatial markers in the real-time perceived image.

Abstract: Some systems include a memory, and a processor coupled to the memory, wherein the processor is configured to: identify one or more spatial markers in a medical data-based image of a patient, identify one or more spatial markers in a real-time perceived image of the patient, wherein the one or more spatial markers in the medical data-based image correspond to an anatomical feature of the patient and the one or more spatial markers in the real-time perceived image correspond to the anatomical feature of the patient, superimpose the medical data-based image of the patient with the real-time perceived image of the patient, and align the one or more spatial markers in the medical data-based image with the respective one or more spatial markers in the real-time perceived image.

Abstract: Neuronal excitation and inhibition of the brain is tracked in the hippocampal CA1 network during a latent period, wherein biomarkers are observed which include a sustained increase in the firing rate of the excitatory postsynaptic field activity, paired with a subsequent decrease in the firing rate of the inhibitory postsynaptic field activity; the mean amplitude profiles of both fEPSP and fEPSP field potential activity during the latent period have characteristic shapes; both excitatory and inhibitory CA1 field activity firing rates are observed to follow a circadian rhythm that drifts during epileptogenesis; the circadian rhythms described are in-phase in controls and anti-phase during epileptogenesis; and the fEPSP rate drifts from a circadian rhythm to a greater extent than the fEPSP rate. An additional biomarker is a change in a circadian rhythm of core body temperature. Therapeutic measures can include thermal, chemical, or electrical modulation, in an open or closed loop process.

Abstract: Neuronal excitation and inhibition of the brain is tracked in the hippocampual CA1 network during a latent period, wherein biomarkers are observed which include a sustained increase in the firing rate of the excitatory postsynaptic field activity, paired with a subsequent decrease in the firing rate of the inhibitory postsynaptic field activity within the CA1 region of the hippocampus; the mean amplitude profiles of both fEPSP and fIPSP field potential activity during the latent period have characteristic shapes; both excitatory and inhibitory CA1 field activity firing rates are observed to follow a circadian rhythm that drifts during epileptogenesis; the circadian rhythms described are in-phase in controls and anti-phase during epileptogenesis; and the fEPSP rate drifts from a circadian rhythm to a greater extent than the fIPSP rate. An additional biomarker is a change in a circadian rhythm of core body temperature.